You are here: Industry Insights > pembrolizumab

News List

FDA Grants Accelerated Approval for Pembrolizumab plus Lenvatinib americanpharmaceuticalreview
September 19, 2019
The Food and Drug Administration (FDA) granted accelerated approval to the combination of pembrolizumab (KEYTRUDA, Merck) plus lenvatinib (LENVIMA, Eisai) for the treatment of patients with ...
FDA Approves Keytruda (pembrolizumab) for the Treatment of Metastatic Small Cell Lung Cancer (SCLC) drugs
June 19, 2019
FDA Approves Keytruda (pembrolizumab) for the Treatment of Metastatic Small Cell Lung Cancer (SCLC).
FDA Approves Keytruda (pembrolizumab) for First-Line Treatment of Head and Neck Squamous Cell Carcinoma drugs
June 12, 2019
FDA Approves Keytruda (pembrolizumab) for First-Line Treatment of Head and Neck Squamous Cell Carcinoma.
Pembrolizumab trumps chemotherapy in recurrent head and neck cancer pharmaceutical-technology
June 05, 2019
Research has shown that immunotherapy pembrolizumab alone and in combination with chemotherapy is a more efficacious first line treatment for head and neck cancer that has returned than aggressive chemotherapy.
ASCO: Pembrolizumab Noninferior to Chemo in Advanced Gastric Cancer drugs
June 04, 2019
ASCO: Pembrolizumab Noninferior to Chemo in Advanced Gastric Cancer.
FDA Approves Pembrolizumab for Merkel Cell Carcinoma americanpharmaceuticalreview
December 21, 2018
On December 19, 2018, the Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab (KEYTRUDA, Merck & Co. Inc.) for ....
EC green-lights MSD’s Keytruda combo for lung cancer pharmatimes
November 27, 2018
The European Commission has approved MSD’s Keytruda for use in combination with Eli Lilly’s Alimta and platinum-based chemotherapy for the first-line treatment of some advanced lung cancers.
Thousands of lung cancer patients to get NHS access to Keytruda biospectrumasia
November 26, 2018
MSD’s Keytruda should be funded on the NHS via the Cancer Drugs Fund for patients with the certain forms of lung cancer, according to draft guidance from the National Institute for Health
MSD’s Keytruda shows benefit in oesophageal cancer trial pharmatimes
November 19, 2018
MSD’s Keytruda has shown promise in a late-stage trial testing its safety and efficacy in patients with advanced or metastatic esophageal or esophagogastric junction carcinoma.
FDA Grants Accelerated Approval to Pembrolizumab for Hepatocellular Carcinoma americanpharmaceuticalreview
November 14, 2018
FDA Grants Accelerated Approval to Pembrolizumab for Hepatocellular Carcinoma

Previous page 1 2 3 4 Next page